Finance Watch: Exo Raises $78m To Advance Exosite-Targeting Small Molecules

Platform Designed For More Precisely Targeted Drugs

Also, Atlas Venture and Advent France Biotechnology raise new venture capital funds, Corium secures $235m in debt to commercialize ADHD drug and CBMG leads recent VC financings with $120m series A round.

Finance Watch Private Company

Exo Therapeutics, Inc. launched in December with $25m in series A venture capital and has advanced its ExoSight technology platform far enough since then to justify a $78m series B round that the company announced on 5 October. It plans to use the financing to advance initial drug candidates that target exosites – unique binding pockets that may be able to reprogram enzyme activity – towards the clinic. Exo will also continue to invest in the ExoSight platform.

“Exosites are found abundantly across the proteome, so part of the intent with this series B was to enable us...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.